Research ExplorerPublicationsCurrent Treatment Practices and Prognostic Factors in Early-...

Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer-An Analysis of the NOGGO/JAGO

Standard

Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer-An Analysis of the NOGGO/JAGO. / Heublein, Sabine; Baum, Joanna; Jaeger, Anna; Grimm-Glang, Donata; Olthoff, Julia; Braicu, Elena Ioana; Azzam Nieto, Osama; Hassdenteufel, Kathrin; Schmalfeldt, Barbara; Hanker, Lars; Wallwiener, Markus; Schneeweiss, Andreas; Sehouli, Jalid; Pietzner, Klaus.

In: CANCERS, Vol. 15, No. 7, 2038, 29.03.2023.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Heublein, S, Baum, J, Jaeger, A, Grimm-Glang, D, Olthoff, J, Braicu, EI, Azzam Nieto, O, Hassdenteufel, K, Schmalfeldt, B, Hanker, L, Wallwiener, M, Schneeweiss, A, Sehouli, J & Pietzner, K 2023, 'Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer-An Analysis of the NOGGO/JAGO', CANCERS, vol. 15, no. 7, 2038. https://doi.org/10.3390/cancers15072038

APA

Heublein, S., Baum, J., Jaeger, A., Grimm-Glang, D., Olthoff, J., Braicu, E. I., Azzam Nieto, O., Hassdenteufel, K., Schmalfeldt, B., Hanker, L., Wallwiener, M., Schneeweiss, A., Sehouli, J., & Pietzner, K. (2023). Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer-An Analysis of the NOGGO/JAGO. CANCERS, 15(7), [2038]. https://doi.org/10.3390/cancers15072038

Vancouver

Heublein S, Baum J, Jaeger A, Grimm-Glang D, Olthoff J, Braicu EI et al. Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer-An Analysis of the NOGGO/JAGO. CANCERS. 2023 Mar 29;15(7). 2038. https://doi.org/10.3390/cancers15072038

Bibtex

@article{2375e4fcaf5044e7ada8e2b81a17fd87,
title = "Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer-An Analysis of the NOGGO/JAGO",
abstract = "BACKGROUND: Surgery is the backbone of early-stage ovarian cancer (OC) management. However, in practice, there is disagreement about the extent of surgical staging and whether additional adjuvant treatment should be provided. As omitting relevant diagnostic or therapeutic procedures might lead to undertreatment, we aimed to structurally investigate treatment practice in addition to prognostic factors in a multicentre series of patients (pts) diagnosed with early-stage OC.PATIENTS: Within this retrospective, multicentre study, medical records of 379 pts who had undergone surgery for suspected early-stage OC between January 2014 and March 2020 were analysed.RESULTS: Of the 379 patients, 292 had pT stage 1a-2a and had complete data on the extent of surgical staging. At least one surgical step was omitted in 100 pts (34.2%). Complete surgical staging (n = 192; (65.8%)) was more often performed in high-grade serous OC and was independent of the healthcare level of the hospital where the initial diagnosis was made. Missing to take peritoneal biopsies was associated with reduced relapse-free-survival in incompletely staged, pT1 cases (p = 0.03). About every second patient (46.7%) with a final stage lower than FIGO IIB and treated with adjuvant chemotherapy received combination chemotherapy. BRCA1 and BRCA2 testing was only performed in a subset of pts, and mutations were detected in 18% (14/79) and 9% (7/85) pts, respectively.CONCLUSIONS: This study helps to increase our understanding of early-stage OC treatment and prognosis. In addition to treating patients in compliance with current guidelines, the need for BRCA testing should also be considered for early-stage OC.",
author = "Sabine Heublein and Joanna Baum and Anna Jaeger and Donata Grimm-Glang and Julia Olthoff and Braicu, {Elena Ioana} and {Azzam Nieto}, Osama and Kathrin Hassdenteufel and Barbara Schmalfeldt and Lars Hanker and Markus Wallwiener and Andreas Schneeweiss and Jalid Sehouli and Klaus Pietzner",
year = "2023",
month = mar,
day = "29",
doi = "10.3390/cancers15072038",
language = "English",
volume = "15",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

RIS

TY - JOUR

T1 - Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer-An Analysis of the NOGGO/JAGO

AU - Heublein, Sabine

AU - Baum, Joanna

AU - Jaeger, Anna

AU - Grimm-Glang, Donata

AU - Olthoff, Julia

AU - Braicu, Elena Ioana

AU - Azzam Nieto, Osama

AU - Hassdenteufel, Kathrin

AU - Schmalfeldt, Barbara

AU - Hanker, Lars

AU - Wallwiener, Markus

AU - Schneeweiss, Andreas

AU - Sehouli, Jalid

AU - Pietzner, Klaus

PY - 2023/3/29

Y1 - 2023/3/29

N2 - BACKGROUND: Surgery is the backbone of early-stage ovarian cancer (OC) management. However, in practice, there is disagreement about the extent of surgical staging and whether additional adjuvant treatment should be provided. As omitting relevant diagnostic or therapeutic procedures might lead to undertreatment, we aimed to structurally investigate treatment practice in addition to prognostic factors in a multicentre series of patients (pts) diagnosed with early-stage OC.PATIENTS: Within this retrospective, multicentre study, medical records of 379 pts who had undergone surgery for suspected early-stage OC between January 2014 and March 2020 were analysed.RESULTS: Of the 379 patients, 292 had pT stage 1a-2a and had complete data on the extent of surgical staging. At least one surgical step was omitted in 100 pts (34.2%). Complete surgical staging (n = 192; (65.8%)) was more often performed in high-grade serous OC and was independent of the healthcare level of the hospital where the initial diagnosis was made. Missing to take peritoneal biopsies was associated with reduced relapse-free-survival in incompletely staged, pT1 cases (p = 0.03). About every second patient (46.7%) with a final stage lower than FIGO IIB and treated with adjuvant chemotherapy received combination chemotherapy. BRCA1 and BRCA2 testing was only performed in a subset of pts, and mutations were detected in 18% (14/79) and 9% (7/85) pts, respectively.CONCLUSIONS: This study helps to increase our understanding of early-stage OC treatment and prognosis. In addition to treating patients in compliance with current guidelines, the need for BRCA testing should also be considered for early-stage OC.

AB - BACKGROUND: Surgery is the backbone of early-stage ovarian cancer (OC) management. However, in practice, there is disagreement about the extent of surgical staging and whether additional adjuvant treatment should be provided. As omitting relevant diagnostic or therapeutic procedures might lead to undertreatment, we aimed to structurally investigate treatment practice in addition to prognostic factors in a multicentre series of patients (pts) diagnosed with early-stage OC.PATIENTS: Within this retrospective, multicentre study, medical records of 379 pts who had undergone surgery for suspected early-stage OC between January 2014 and March 2020 were analysed.RESULTS: Of the 379 patients, 292 had pT stage 1a-2a and had complete data on the extent of surgical staging. At least one surgical step was omitted in 100 pts (34.2%). Complete surgical staging (n = 192; (65.8%)) was more often performed in high-grade serous OC and was independent of the healthcare level of the hospital where the initial diagnosis was made. Missing to take peritoneal biopsies was associated with reduced relapse-free-survival in incompletely staged, pT1 cases (p = 0.03). About every second patient (46.7%) with a final stage lower than FIGO IIB and treated with adjuvant chemotherapy received combination chemotherapy. BRCA1 and BRCA2 testing was only performed in a subset of pts, and mutations were detected in 18% (14/79) and 9% (7/85) pts, respectively.CONCLUSIONS: This study helps to increase our understanding of early-stage OC treatment and prognosis. In addition to treating patients in compliance with current guidelines, the need for BRCA testing should also be considered for early-stage OC.

U2 - 10.3390/cancers15072038

DO - 10.3390/cancers15072038

M3 - SCORING: Journal article

C2 - 37046699

VL - 15

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 7

M1 - 2038

ER -